LRRK2 and Crohn disease: LRRK2 variants were shown to modulate the risk for Crohn’s disease, a chronic inflammatory bowel disease, and LRRK2 kinase activity was shown to influence microglial activation and pro-inflammatory cytokine production (Hui et al., 2018; Moehle et al., 2012).